Table 2.
Summary HSV Based Vectors for Vaccination
| HSV Strain | Genetic Modification | Therapeutic Transgenes | Clinical Indications | Ref. |
|---|---|---|---|---|
| Replication-Competent Vectors | ||||
| NV1020 (HSV-1) | Deletion in one copy of ICP34.5 + tk under ICP4 promoter control + deletion in UL24, 55 and 56 | none | Anti HSV vaccine | [121, 122] |
| RAV9395 (HSV-2) | Deletion in both copy of ICP34.5 + deletion in UL55 and 56 + deletion in both copy of ORF P | none | Anti HSV vaccine | [118] |
| AD-472 (HSV-2) | Deletion in both copy of ICP34.5 + deletion in UL55 and 56 + deletion in both copy of ORF P + deletion of UL43.5 + deletion of US10-12 | none | Anti HSV vaccine | [126, 127] |
| NS-gEnull (HSV-1) | Deletion of US8 | none | Anti HSV vaccine | [128] |
| ImmunoVEXHSV2 | Deletion of genes involved in immune evasion | none | Anti HSV vaccine | www.biovex.com |
| Replication-Defective Vectors | ||||
| dl5-29 (HSV-2) | Deletion of UL5 and 29 | none | Anti HSV vaccine | [99, 103, 105] |
| dl5-29-41L (HSV-2) | Deletion of UL5 and 29 + deletion of UL41 | none | Anti HSV vaccine | [99, 104, 105] |
| DISC-gH (HSV-1) | Deletion of gH | none | Anti HSV vaccine | [101, 106] |
| DISC gH (HSV-2) | Deletion of gH | mGM-CSF or hIL-12 | Anti HSV vaccine and anti tumour vaccine | [108, 109] |
| CJ9gD (HSV-1) | Deletion of UL9 | Over-expression of gD | Anti HSV vaccine | [110-112] |
| TOH-OVA (HSV-1) | Deletion of ICP4, 22, 27, and 47 | Ovalbumin | Anti bacterial infections | [94] |
| d106 (HSV-1) | Deletion of ICP4, 22, and 27 | HIV-1 Tat | Anti HIV vaccine | [114] |
| d81 (HSV-1) | Deletion of ICP27 | SIV Env and Nef | Anti SIV vaccine | [115] |
| HSV-SIV d106 (HSV-1) | Deletion of ICP4, 22, 27, and 47 | SIV Gag, Env, and Tat-Rev-Nef fusion protein | Anti SIV vaccine | [95, 116] |
| d106S (HSV-1) | Deletion of ICP4, 22, 27, and 47 + increased acyclovir resistance | HIV-1 Tat | Anti HIV vaccine | [117] |